Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
9.95
-0.62 (-5.87%)
At close: Nov 20, 2026, 4:00 PM EST
10.07
+0.12 (1.21%)
After-hours: Nov 20, 2026, 7:54 PM EST
Summit Therapeutics Employees
Summit Therapeutics had 265 employees as of December 31, 2025. The number of employees increased by 106 or 66.67% compared to the previous year. That makes Summit Therapeutics the 24,820th largest employer in the world and 3,170th in the United States.
Employees
265
Change (1Y)
106
Growth (1Y)
66.67%
Revenue / Employee
n/a
Profits / Employee
-$3,142,192
Market Cap
7.96B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 265 | 106 | 66.67% |
| Dec 31, 2024 | 159 | 54 | 51.43% |
| Dec 31, 2023 | 105 | 28 | 36.36% |
| Dec 31, 2022 | 77 | -33 | -30.00% |
| Dec 31, 2021 | 110 | 29 | 35.80% |
| Dec 31, 2020 | 81 | 11 | 15.71% |
| Dec 31, 2019 | 70 | 9 | 14.75% |
| Dec 31, 2018 | 61 | -15 | -19.74% |
| Dec 31, 2017 | 76 | 36 | 90.00% |
| Dec 31, 2016 | 40 | 3 | 8.11% |
| Dec 31, 2015 | 37 | 14 | 60.87% |
| Dec 31, 2014 | 23 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Twist Bioscience | 1,080 |
| Madrigal Pharmaceuticals | 915 |
| Corcept Therapeutics | 730 |
| Cytokinetics | 673 |
| Vaxcyte | 507 |
| Rhythm Pharmaceuticals | 414 |
| TG Therapeutics | 399 |
| Praxis Precision Medicines | 168 |
SMMT News
- 1 day ago - Summit Therapeutics to Host Corporate Update and Operational Progress Call on November 30, 2026 - Business Wire
- 2 days ago - Summit Therapeutics price target lowered to $11 from $13 at Leerink - TheFly
- 3 days ago - Bernstein downgrades Summit Therapeutics to Underperform, lowers target to $8.30 - TheFly
- 3 days ago - Summit Therapeutics downgraded to Underperform from Market Perform at Bernstein - TheFly
- 3 days ago - Summit Therapeutics initiates new global Phase 3 trial of ivonescimab - TheFly
- 3 days ago - Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase III HARMONi-10 Study in Unresectable Stage III Non-Small Cell Lung Cancer - Business Wire
- 3 days ago - Summit Therapeutics' stock tumbles again as FDA recommends new trial for lung-cancer drug - Market Watch
- 5 days ago - Summit Therapeutics falls -14.4% - TheFly